GSEP
ONC

Golden State Equity Partners’s BeOne Medicines Ltd ONC Stock Holding History

Golden State Equity Partners’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33
Closed -$9.8K – 1866
2026
Q1 		$9.8K Buy
+33
New +$10.7K ﹤0.01% 1302

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Golden State Equity Partners's ONC Position: Q2 2026 in Review

Golden State Equity Partners sold out of BeOne Medicines Ltd (ONC) in Q2 2026, closing a stake of 33 shares — an estimated $9.8K sold.

Golden State Equity Partners first reported a position in ONC in Q1 2026 and held it in 1 quarter. The position peaked at $9.8K in Q1 2026. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • Golden State Equity Partners reported no remaining BeOne Medicines Ltd position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 33 BeOne Medicines Ltd shares in Q2 2026, an estimated $9.8K.
  • Golden State Equity Partners first reported a position in BeOne Medicines Ltd in Q1 2026 and held it in 1 quarter.
  • Golden State Equity Partners's BeOne Medicines Ltd position peaked at $9.8K in Q1 2026.
  • 282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.